22nd Century Group, Inc. (XXII) Announces Exclusive Worldwide Agreement with KeyGene – Marijuana Stocks


Strategic collaboration will bolster 22nd Century’s position as a international leader in hemp/cannabis genetics.

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology business that is a leader in tobacco harm reduction, Incredibly Low Nicotine Content material tobacco, and hemp/cannabis analysis, announced right now that the Enterprise has entered into a worldwide strategic analysis and improvement agreement with KeyGene, www.keygene.com, a international leader in plant analysis involving higher-worth genetic traits and enhanced crop yields. This exclusive, worldwide collaboration will concentrate on building hemp/cannabis plants with exceptional cannabinoid profiles for health-related and therapeutic use amongst other applications.

Cannabinoids are naturally occurring compounds located in hemp and in cannabis that have been linked to a quantity of prospective health-related advantages. The mix, concentration, and qualities of these cannabinoids differ extensively and can be optimized by way of molecular breeding and other contemporary crop improvement technologies that have been utilized extensively in other crops, but which have been utilized hardly ever in hemp and cannabis varieties.

The 22nd Century-KeyGene collaboration supplies 22nd Century access to a exceptional suite of crop innovation platforms, like genomics, molecular genetics, trait discovery and breeding technologies. Beneath the agreement, 22nd Century will hold exclusive worldwide rights to all hemp/cannabis plant lines, intellectual home on metabolic traits, and analysis final results that are created by way of this strategic partnership. The concentrate of the collaboration will include things like:

(i) Developing a cutting-edge genetic database which utilizes the final results of genomic analyses of numerous hundred current, exceptional hemp/cannabis plant lines for use in the acceleration of the Company’s improvement and licensing of uniquely characterized and enhanced hemp/cannabis plants

(ii) Enhancing genetic variation to empower 22nd Century’s improvement of new and substantially enhanced varieties of hemp/cannabis plant lines and varieties with hugely desirable cannabinoid profiles optimized for medicinal or therapeutic applications

(iii) Developing a proprietary and business-major higher-resolution “molecular genetic map” of the whole cannabis plant genome to facilitate fast, expense-helpful breeding of revolutionary varieties of hemp/cannabis plants with distinctive agronomic traits

(iv) Analyzing the genomic sequences of a number of species of the hemp/cannabis plant and identifying shared genetic markers, enabling 22nd Century to create enhanced industrial hemp/cannabis plant lines much more swiftly than by way of standard plant breeding approaches and

(v) Initiating the fast-cycle generation of hemp/cannabis plant lines with distinctive cannabinoid and terpene profiles to generate elite lines.

“22nd Century’s exclusive international collaboration with KeyGene is anticipated to yield really exceptional and novel medicinal cannabinoid profiles and other hugely desirable agronomic traits,” explained Henry Sicignano III, President and Chief Executive Officer of 22nd Century Group. “Combined with 22nd Century’s current hemp/cannabis technologies, like our current proprietary hemp/cannabis plant lines, the KeyGene plan will bolster 22nd Century’s position as a international leader in hemp/cannabis genetics and, we anticipate, will lead to considerable commercialization ventures and other possibilities.”

“22nd Century’s function with KeyGene will tremendously boost our Company’s potential to use the cannabis genome and will allow us to accelerate molecular breeding of new hemp/cannabis plant varieties,” stated Dr. Juan Tamburrino, 22nd Century’s Vice President of Study and Improvement. “We think our collaboration with KeyGene will create proprietary understanding and will contribute tremendously to our intellectual home and patent portfolio.”

Perform on the plan will happen in a number of areas in the United States and the Netherlands.

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology business focused on technologies which enables it to boost or lower the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants by way of genetic engineering and plant breeding. The Company’s major mission in tobacco is to cut down the harm triggered by smoking. The Company’s major mission in hemp/cannabis is to create proprietary hemp strains for essential new medicines and agricultural crops. Visit www.xxiicentury.com and www.botanicalgenetics.com for much more information and facts.

Cautionary Note With regards to Forward-Hunting Statements: This press release consists of forward-searching information and facts, like all statements that are not statements of historical reality with regards to the intent, belief or existing expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, like but not restricted to our future income expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and comparable expressions and variations thereof are intended to determine forward-searching statements. We can not assure future final results, levels of activity or overall performance. You should really not spot undue reliance on these forward-searching statements, which speak only as of the date that they had been produced. These cautionary statements should really be thought of with any written or oral forward-searching statements that we might situation in the future. Except as essential by applicable law, like the securities laws of the United States, we do not intend to update any of the forward-searching statements to conform these statements to reflect actual final results, later events or situations, or to reflect the occurrence of unanticipated events. You should really meticulously assessment and think about the several disclosures produced by us in our annual report on Type 10-K for the fiscal year ended December 31, 2018, filed on March six, 2019, like the section entitled “Risk Things,” and our other reports filed with the U.S. Securities and Exchange Commission which try to advise interested parties of the dangers and elements that might have an effect on our business enterprise, monetary situation, final results of operation and money flows. If one particular or much more of these dangers or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual final results might differ materially from these anticipated or projected.


Latest posts